| [1] |
Wu Y, He S, Cao M, et al. Comparative analysis of cancer statistics in China and the United States in 2024[J]. Chin Med J (Engl), 2024, 137(24): 3093-3100.
|
| [2] |
Khan SH, Anees M, Zofair SFF, et al. Fucoidan based polymeric nanoparticles encapsulating epirubicin: a novel and effective chemotherapeutic formulation against colorectal cancer[J]. Int J Pharm, 2024, 664: 124622.
|
| [3] |
Gao R, Yue B, Lv C, et al. Targeted inhibition of Gus-expressing Enterococcus faecalis to promote intestinal stem cell and epithelial renovation contributes to the relief of irinotecan chemotoxicity by dehydrodiisoeugenol[J]. Acta Pharmaceutica Sinica B, 2024, 14(12): 5286-5304.
|
| [4] |
Kawasaki Y, Kakimoto K, Tanaka Y, et al. Relationship between chemotherapy-induced diarrhea and intestinal microbiome composition[J]. Digestion, 2023, 104(5): 357-369.
|
| [5] |
Ciernikova S, Mego M, Chovanec M. Exploring the potential role of the gut microbiome in chemotherapy-induced neurocognitive disorders and cardiovascular toxicity[J]. Cancers (Basel), 2021, 13(4): 782.
|
| [6] |
Wei L, Wen XS, Xian CJ. Chemotherapy-induced intestinal microbiota dysbiosis impairs mucosal homeostasis by modulating toll-like receptor signaling pathways[J]. Int J Mol Sci, 2021, 22(17): 9474.
|
| [7] |
Mahooti M, Abdolalipour E, Sanami S, et al. Inflammatory modulation effects of probiotics: a safe and promising modulator for cancer prevention[J]. Current Microbiology, 2024, 81(11): 372.
|
| [8] |
Griffin ME, Espinosa J, Becker JL, et al. Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy[J]. Science, 2021, 373(6558): 1040-1046.
|
| [9] |
严明旭，王雅琪，申丽君，等. 错配修复完整及微卫星稳定型结直肠癌免疫治疗相关生物标志物的研究进展[J]. 中华胃肠外科杂志，2025，28(7)：796-803.
|
| [10] |
Dahlgren D, Lennernäs H. Review on the effect of chemotherapy on the intestinal barrier: epithelial permeability, mucus and bacterial translocation[J]. Biomed Pharmacother, 2023, 162: 114644.
|
| [11] |
Yu QQ, Zhang H, Guo Y, et al. The intestinal redox system and its significance in chemotherapy-induced intestinal mucositis[J]. Oxid Med Cell Longev, 2022, 2022: 7255497.
|
| [12] |
Shuwen H, Xi Y, Yuefen P, et al. Effects of postoperative adjuvant chemotherapy and palliative chemotherapy on the gut microbiome in colorectal cancer[J]. Microb Pathog, 2020, 149: 104343.
|
| [13] |
Cecati M, Pozzi V, Pompei V, et al. Cisplatin as a xenobiotic agent: molecular mechanisms of actions and clinical applications in oncology[J]. Journal of Xenobiotics, 2026, 16(1): 9.
|
| [14] |
Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment[J]. Science, 2013, 342(6161): 967-970.
|
| [15] |
Ayna A, Caglayan C, Taysi S. Cellular and molecular mechanisms of oxidative DNA damage and repair[J]. Medicina, 2025, 61(11): 2013.
|
| [16] |
García-Alfonso P, Muñoz Martín AJ, Ortega Morán L, et al. Oral drugs in the treatment of metastatic colorectal cancer[J]. Ther Adv Med Oncol, 2021, 13: 17588359211009001.
|
| [17] |
Yang J, Liu KX, Qu JM, et al. The changes induced by cyclophosphamide in intestinal barrier and microflora in mice[J]. Eur J Pharmacol, 2013, 714(1-3): 120-124.
|
| [18] |
Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide[J]. Science, 2013, 342(6161): 971-976.
|
| [19] |
Lee Y, Awasthi A, Yosef N, et al. Induction and molecular signature of pathogenic TH17 cells[J]. Nat Immunol, 2012, 13(10): 991-999.
|
| [20] |
Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling[J]. Nature, 2010, 467(7318): 967-971.
|
| [21] |
Daillère R, Vétizou M, Waldschmitt N, et al. Enterococcus hirae and barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects[J]. Immunity, 2016, 45(4): 931-943.
|
| [22] |
Omran MM, Fouda MS, Mekkawy SA, et al. Molecular biomarkers and signaling pathways of cancer stem cells in colorectal cancer[J]. Technology in Cancer Research & Treatment, 2024, 23: 15330338241254061.
|
| [23] |
Liu H, Du J, Chao S, et al. Fusobacterium nucleatum promotes colorectal cancer cell to acquire stem cell-like features by manipulating lipid droplet-mediated numb degradation[J]. Adv Sci (Weinh), 2022, 9(12): e2105222.
|
| [24] |
Zhang S, Yang Y, Weng W, et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer[J]. J Exp Clin Cancer Res, 2019, 38(1): 14.
|
| [25] |
Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy[J]. Cell, 2017, 170(3): 548-563.e16.
|
| [26] |
Heindryckx F, Sjöblom M. Endoplasmic reticulum stress in the pathogenesis of chemotherapy-induced mucositis: physiological mechanisms and therapeutic implications[J]. Acta Physiologica, 2024, 240(8): e14188.
|
| [27] |
Gowda M, Venkatraman A, Mechler-Hickson A, et al. Toll like receptors in the larynx: implications for laryngeal immunology[J]. The Laryngoscope, 2025, 135(10): 3815-3823.
|
| [28] |
Yang Y, Feng R, Wang YZ, et al. Toll-like receptors: triggers of regulated cell death and promising targets for cancer therapy[J]. Immunol Lett, 2020, 223: 1-9.
|
| [29] |
Elshabrawy HA, Essani AE, Szekanecz Z, et al. TLRs, future potential therapeutic targets for RA[J]. Autoimmun Rev, 2017, 16(2): 103-113.
|
| [30] |
Justino PFC, Franco AX, Pontier-Bres R, et al. Modulation of 5-fluorouracil activation of toll-like/MyD88/NF-κB/MAPK pathway by Saccharomyces boulardii CNCM I-745 probiotic[J]. Cytokine, 2020, 125: 154791.
|
| [31] |
Tsunoda SM, Gonzales C, Jarmusch AK, et al. Contribution of the gut microbiome to drug disposition, pharmacokinetic and pharmacodynamic variability[J]. Clin Pharmacokinet, 2021, 60(8): 971-984.
|
| [32] |
Stringer AM, Gibson RJ, Logan RM, et al. Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats[J]. Cancer Biol Ther, 2008, 7(12): 1919-1925.
|
| [33] |
Bhatt AP, Pellock SJ, Biernat KA, et al. Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy[J]. Proc Natl Acad Sci USA, 2020, 117(13): 7374-7381.
|
| [34] |
Mego M, Chovanec J, Vochyanova-Andrezalova I, et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study[J]. Complement Ther Med, 2015, 23(3): 356-362.
|
| [35] |
Özkan A, LoGrande NT, Feitor JF, et al. Intestinal organ chips for disease modelling and personalized medicine[J]. Nat Rev Gastroenterol Hepatol, 2024, 21(11): 751-773.
|
| [36] |
Xie P, Ma Z, Yang X, et al. The regulatory effects and mechanisms of plant food-derived bioactive components on gut barrier function and intestinal homeostasis: a comprehensive review[J]. Critical Reviews in Food Science and Nutrition, 2025, 65(31): 7810-7833.
|
| [37] |
Qu R, Zhang Y, Ma Y, et al. Role of the gut microbiota and its metabolites in tumorigenesis or development of colorectal cancer[J]. Adv Sci (Weinh), 2023, 10(23): e2205563.
|
| [38] |
Xing C, Wang M, Ajibade AA, et al. Microbiota regulate innate immune signaling and protective immunity against cancer[J]. Cell Host Microbe, 2021, 29(6): 959-974.e7.
|
| [39] |
Alli SR, Gorbovskaya I, Liu JCW, et al. The gut microbiome in depression and potential benefit of prebiotics, probiotics and synbiotics: a systematic review of clinical trials and observational studies[J]. Int J Mol Sci, 2022, 23(9): 4494.
|
| [40] |
Kadyan S, Park G, Hochuli N, et al. Resistant starches from dietary pulses improve neurocognitive health via gut-microbiome-brain axis in aged mice[J]. Front Nutr, 2024, 11: 1322201.
|
| [41] |
Tao J, Li S, Gan RY, et al. Targeting gut microbiota with dietary components on cancer: effects and potential mechanisms of action[J]. Crit Rev Food Sci Nutr, 2020, 60(6): 1025-1037.
|
| [42] |
Peng W, Fan X, Shi H, et al. Gut microbiota and chemotherapy-induced gastrointestinal toxicity: mechanisms and intervention strategies[J]. Dig Dis, 2025, 14: 1-22.
|
| [43] |
Deng Y, Hou X, Wang H, et al. Influence of gut microbiota-mediated immune regulation on response to chemotherapy[J]. Pharmaceuticals (Basel), 2024, 17(5): 604.
|
| [44] |
Fernandes MR, Aggarwal P, Costa RGF, et al. Targeting the gut microbiota for cancer therapy[J]. Nat Rev Cancer, 2022, 22(12): 703-722.
|
| [45] |
Liu W, Xu J, Pi Z, et al. Untangling the web of intratumor microbiota in lung cancer[J]. Biochim Biophys Acta Rev Cancer, 2023, 1878(6): 189025.
|
| [46] |
Li R, Hu Y, Liu Y, et al. Fecal microbiota transplantation augments 5-fluorouracil efficacy in pancreatic cancer via gut microbiota modulation[J]. Front Microbiol, 2025, 16: 1548027.
|
| [47] |
Wang X, Geng Q, Jiang H, et al. Fecal microbiota transplantation enhanced the effect of chemoimmunotherapy by restoring intestinal microbiota in LLC tumor-bearing mice[J]. BMC Immunol, 2025, 26(1): 30.
|
| [48] |
Liu Y, Li X, Chen Y, et al. Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay[J]. Front Microbiol, 2025, 16: 1556827.
|
| [49] |
Zhou Y, Li Q, Wu Y, et al. Synergistic brilliance: engineered bacteria and nanomedicine unite in cancer therapy[J]. Adv Mater, 2024, 36(21): e2313953.
|
| [50] |
Wang Z, Sun W, Hua R, et al. Promising dawn in tumor microenvironment therapy: engineering oral bacteria[J]. Int J Oral Sci, 2024, 16(1): 24.
|
| [51] |
Chen H, Zhu Y, Zhang C, et al. Engineered bacteria in tumor immunotherapy[J]. Cancer Lett, 2024, 589: 216817.
|